Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES , Nov. 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ: QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

QTRX Investors Have Opportunity to Join Quanterix Corporation Fraud Investigation with the Schall Law Firm

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Quanterix Corporation for potential violations of securities laws

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Quanterix Corporation (NASDAQ: QTRX) resulting from allegations that Quanterix may have issued materially misleading business information to the investing public. So What: If you purchased Quanterix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang.

Rosen Law Firm Encourages Quanterix Corporation Investors to Inquire About Securities Class Action Investigation – QTRX

LOS ANGELES, CA / ACCESSWIRE / November 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Quanterix Corporation For Securities Fraud

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

QTRX STOCK ALERT: Levi & Korsinsky Notifies Quanterix Corporation Investors of an Ongoing Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that is investigating potential claims against Quanterix Corporation ("Quanterix" or the "Company")( NASDAQ:QTRX) on behalf of Quanterix stockholders. The investigation concerns whether Quanterix and certain of its officers and/or directors have engaged in securities fraud.

Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating Quanterix Corporation for Potential Violations of Securities Laws

LOS ANGELES, CA / ACCESSWIRE / November 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Investigated For Violating Securities Regulations And Investors With Losses Are Invited To Help The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

Lost Money on Quanterix Corporation(QTRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / November 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

A Securities Fraud Inquiry Has Been Launched Into Quanterix Corporation And The Schall Law Firm Urges Affected Shareholders To Reach Out

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

Quanterix Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - QTRX

LOS ANGELES, CA / ACCESSWIRE / November 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses Are Invited To Help The Schall Law Firm Investigate Whether Quanterix Corporation Defrauded The Public

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Quanterix Corporation's Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / November 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Looked Into For Fraud And Affected Investors Should Reach Out To The Schall Law Firm

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Girard Sharp, LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of Qaunterix Corporation (NASDAQ: QTRX) investors.

INVESTIGATION NOTICE: Girard Sharp Law Firm Encourages Qaunterix Corporation (NASDAQ: QTRX) Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

Levi & Korsinsky Reminds Shareholders of an Investigation into Quanterix Corporation (QTRX) Regarding Potential Securities Fraud Allegations

LOS ANGELES, CA / ACCESSWIRE / November 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Investigated For Fraud And Investors With Losses Should Reach Out To The Schall Law Firm

Quanterix Corporation Being Investigated on Behalf of Quanterix Corporation Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

QTRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Quanterix Corporation investment

LOS ANGELES, CA / ACCESSWIRE / November 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Quanterix Corporation For Violating Securities Laws

Shareholders that lost money on Quanterix Corporation(QTRX) should contact Levi & Korsinsky about Securities Fraud Investigation - QTRX

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Quanterix Corporation (NASDAQ: QTRX) or any of its executive officers violated securities laws by misrepresenting or failing to disclose material information to investors.

Quanterix Corporation Is Now Under Investigation by Johnson Fistel, LLP on Behalf of Shareholders Who Incurred Losses on Their Investments

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company's possible violations of federal securities laws. On November 12, 2024, after market hours, Quanterix disclosed that it had “identified an error related to the capitalization of labor and overhead costs applied to prior periods going back to at least 2021, which impacted the valuation of invent.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Quanterix investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ:QTRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 12, 2024, after market hours, Quanterix disclosed that it had “identified an error related to the capitalization of labor and overhead costs applied to prior.

The Law Offices of Frank R. Cruz Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors

Quanterix Corporation (NASDAQ:QTRX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Vandana Sriram - CFO Masoud Toloue - President and CEO Conference Call Participants Jake Allen - Goldman Sachs Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Thomas DeBourcy - Nephron Research Operator Thank you for standing by. My name is Andrea and I will be your conference operator today.

News for Quanterix Stock (QTRX)